Hemab
Henrik Østergaard, PhD, MSc, serves as Scientific Director at Hemab. He has 18 years of experience within early biopharmaceutical drug discovery and development, most recently in the role as Scientific Director at Novo Nordisk A/S. With a particular focus on early innovation, protein engineering, and enzymology, Henrik has led several drug development projects within the hemophilia space, of which Refixia® is currently on the market. He is the author of numerous scientific publications and an inventor of patents covering new technologies and therapeutic molecules. He earned an MSc and a PhD from the Technical University of Denmark.
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.